Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31750396 | 1.00 | S1PR2 (0.46) | S1PR2CSNK1A1CLK4ALDH1A1IDH1 | |
| SCHEMBL19565835 | 0.83 | ALDH1A1 (0.40) | S1PR2CSNK1A1CLK4ALDH1A1S1PR1 | |
| SCHEMBL29505699 | 0.78 | UHRF1 (0.46) | S1PR2CSNK1A1CLK4ALDH1A1IDH1 | |
| SCHEMBL317517 | 0.78 | UHRF1 (0.46) | S1PR2CSNK1A1CLK4ALDH1A1IDH1 | |
| SCHEMBL30445578 | 0.78 | CSNK1A1 (0.44) | CSNK1A1CLK4ALDH1A1NPSR1TDP1 | |
| SCHEMBL1286023 | 0.78 | CSNK1A1 (0.44) | CSNK1A1CLK4ALDH1A1NPSR1TDP1 | |
| SCHEMBL21927619 | 0.77 | EGLN2 (0.41) | S1PR2CSNK1A1CLK4ALDH1A1IDH1 | |
| SCHEMBL5555501 | 0.76 | GPBAR1 (0.45) | ALDH1A1NPSR1TDP1TSHRLRRK2 | |
| SCHEMBL14068317 | 0.75 | S1PR2 (0.37) | S1PR2CSNK1A1CLK4ALDH1A1IDH1 | |
| SCHEMBL21296119 | 0.75 | CSNK1A1 (0.41) | S1PR2CSNK1A1CLK4ALDH1A1S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12358903-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240383853-A1 | OXIMES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-11-21 | — | — | US | disclosed |
| CN-115605466-B | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4408533-A1 | OXIMES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-08-07 | — | — | EP | disclosed |
| CN-118139842-A | Oximes and their use in the treatment of GBA related diseases | 泽拉丹麦有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2024003773-A1 | 2,7-NAPHTHYRIDINE COMPOUNDS AS MASTL INHIBITORS | PFIZER INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673920-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2427444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129379-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| EP-1999110-B1 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB PHARMA SA (BE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090221828-A1 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives | UCB PHARMA, S.A. (BE) | 2009-09-03 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| EP-1999110-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB Pharma, S.A. (BE) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107345-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358903-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | S1PR2 410/4885CSNK1A1 2680/4885CLK4 3976/4885 |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | S1PR2 2945/4885CSNK1A1 963/4885CLK4 4846/4885 |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | NR3C1, NR2C2, RIOX2 | S1PR2 760/4885CSNK1A1 833/4885CLK4 4805/4885 |
| US-20240383853-A1 | OXIMES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | GBA1, GBA2, GBA3 | S1PR2 741/4885CSNK1A1 3479/4885CLK4 4388/4885 |
| US-20140142115-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | S1PR2 1180/4885CSNK1A1 1572/4885CLK4 869/4885 |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | S1PR2 450/4885CSNK1A1 709/4885CLK4 3530/4885 |
| US-20090221828-A1 | Process for Preparing 1-Halo-2,7-Naphthyridinyl Derivatives | NPM1, XPO4, BRD7 | S1PR2 4518/4885CSNK1A1 395/4885CLK4 281/4885 |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | S1PR2 1180/4885CSNK1A1 1572/4885CLK4 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.